Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe
In recent years, the number of trials incorporating health-related quality of life (HRQoL) data has increased. The impact of HRQoL on regulatory decision making in the European context and on clinical practice is not well established. We conducted an analysis of the role of QoL data extracted from t...
Main Authors: | L. Moscetti, I. Sperduti, A. Frassoldati, A. Musolino, C. Nasso, A. Toss, C. Omarini, M. Dominici, F. Piacentini |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-10-01
|
Series: | Breast |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977621004173 |
Similar Items
-
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
by: Claudia Omarini, et al.
Published: (2020-05-01) -
The Role of Exosomes in Breast Cancer Diagnosis
by: Claudia Piombino, et al.
Published: (2021-03-01) -
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus
by: Claudia Omarini, et al.
Published: (2018-01-01) -
Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects
by: Daniela Melchiorri, et al.
Published: (2020-10-01) -
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
by: Omarini C, et al.
Published: (2018-01-01)